March 13, 2008 - -Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos has reached the target enrollment of 840 patients in the pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) for its lead product NOV-002 in combination with first-line chemotherapy... [PDF] Novelos' Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
March
(46)
- Masimo Rainbow SET Pulse CO-Oximetry Effective as ...
- Lilly : US$4.4 Million to the WHO for MDR-TB Progr...
- Nereus Pharmaceuticals : Clinical Trail of NPI-235...
- Masimo : Schiller AG Adopts its Rainbow SET as The...
- Accuray : CyberKnife Radiosurgery Used to Treat Lu...
- Actavis : approval of generic Wellbutrin SR and Zy...
- Merck Statement on the FDA Early Communication of ...
- Kamada : Advancement in its Phase II Trial with Ae...
- EpiCept, Myriad Genetics, Azixa
- Poniard Pharmaceuticals : Additional data presenta...
- AstraZeneca : Phase III Studies Of The Investigati...
- SPO Medical : Shipping PulseOx 6000(TM) and PulseO...
- MicroDose Technologies : Global License to Merck &...
- Mpex Pharmaceuticals : MP-376, Granted U.S. Orphan...
- Arriva Pharmaceuticals : Phase 2b Development of L...
- Cell Therapeutics : European Marketing Authorizati...
- Allegro Diagnostics : to Develop and Commercialize...
- AstraZeneca : Long-Term SYMBICORT® Use In Children...
- Apieron : FDA Clearance of the Insight™ eNO System...
- Genaera : MedImmune Initiation of Phase 2A Trial o...
- MAP Pharmaceuticals : Positive Results From Compar...
- GlobeImmune, Initiation of a Phase 2a Clinical Tri...
- Tongjitang to Enhance Product Portfolio with a Lea...
- AlphaMed Pharmaceuticals has successfully expresse...
- Universal Detection Technology , Anti-Microbial Pr...
- ArQule, Phase 1/2 Clinical Trial Program of ARQ 19...
- Novelos Therapeutics, Pivotal Phase 3 Lung Cancer ...
- Abbott, Genentech, Roche and OSI, Collaboration on...
- Luminex and Abbott, Agreement for Global Distribut...
- Quidel's QuickVue RSV Test : FDA Grants CLIA Waiver
- Altor BioScience , Tissue Factor Antagonists from ...
- Introgen's p53 Immunotherapy INGN 225 in Patients ...
- Inspire, Second Phase 3 Cystic Fibrosis Trial
- Expression Pathology, Research in Identifying Biom...
- Biothera’s Imprime PGG with Avastin Against Cancer
- Response Genetics, ResponseDX Tests to Select Inst...
- Gilead, Aztreonam Lysine 75 mg Powder for Nebulise...
- Alnylam, First Human Proof of Concept for an RNAi ...
- Aerocrine, NIOX MINO: a New Hand-Held Device to Me...
- KaloBios, Phase 1/2 Trial of KB002 Engineered Mono...
- Cerner and UNMHSC, agreement to evaluate dry-powde...
- Talecris Biotherapeutics, 20th Anniversary of Laun...
- Amira Pharmaceuticals and GSK, global agreement fo...
- Asthmatx, Bronchial Thermoplasty in Refractory Ast...
- Orexo, eoxins, new mechanism for asthma and COPD t...
- Boehringer Ingelheim’s BIBW 2992 for the treatment...
-
▼
March
(46)
Mar 14, 2008
Novelos Therapeutics, Pivotal Phase 3 Lung Cancer Trial
March 13, 2008 - -Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos has reached the target enrollment of 840 patients in the pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) for its lead product NOV-002 in combination with first-line chemotherapy... [PDF] Novelos' Press Release -
